Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Exklusiv humanmjölk hos prematura nyfödda och tidig vaskulär åldrande riskfaktorer (NEOVASC) (NEOVASC)

15 september 2026 uppdaterad av: Ursula Kohlendorfer, Prolacta Bioscience

Effekter av en exklusiv diet med människomjölk hos för tidigt födda nyfödda på tidig vaskulär åldrande riskfaktorer (NEOVASC)

Early vascular aging has its origins in fetal and neonatal life. The NEOVASC clinical trial aims to determine the effects of an exclusive human milk diet in extremely preterm infants on long-term cardiovascular health.

Studieöversikt

Status

Rekrytering

Intervention / Behandling

Detaljerad beskrivning

Early vascular aging has its origins in fetal and neonatal life. This early period of life plays an important role in the development of obesity, high blood pressure, abnormalities in lipid metabolism and non-insulin dependent diabetes. Increased cardiovascular risk in formerly preterm infants constitutes a health problem of steadily growing relevance. Emerging evidence suggests that human milk feeding has substantial benefits to the health of all infants, especially for those born prematurely. Unfortunately, human milk alone does not provide sufficient concentrations of nutrients, especially calcium, phosphorus, protein, and fat needed for these infants to grow satisfactorily. For that purpose, fortifiers are used to help increase the nutritional value of human milk.

The NEOVASC study is a multicentric, prospective, randomized, controlled, open and parallel group clinical trial. A total of 200 extremely preterm infants and 100 term infants are recruited for the test and control group, respectively. Infants in the test group (i.e., premature neonates) are randomized to either:

  1. An exclusive human milk diet which contains mother's milk or pasteurized donor human milk and a human milk fortifier until 36 weeks of gestation; OR
  2. Human milk (as long as available) and a human milk fortifier (as long as human milk is available) until a maximum of 32 weeks of gestation and thereafter human milk with a bovine-based fortifier or preterm formula.

After 36 weeks of gestation, human milk with a bovine-based fortifier or preterm formula is used in both groups. As a control group, term-born age-matched controls are included. Participants within this control group are not enrolled at the time of birth but instead recruited in various kindergartens at the age of five. Therefore, data from birth is taken from the mother-child-booklet, which contains clinical records about the pregnancy, birth and early life of children born in Austria. The total study duration is scheduled for 96 months with a recruitment phase of 36 months. Follow-up visits are planned at one, two and five years of age for the test group.

The purpose of the NEOVASC clinical trial is to characterize early life stressors by assessing the effects of a physiological (i.e., human milk-based) nutrition in extremely preterm infants during the vulnerable preterm period on the risk of metabolic and vascular complications in later life. Outcomes include predictors and intermediate components of cardiovascular disease.

Studietyp

Interventionell

Inskrivning (Beräknad)

200

Fas

  • Inte tillämpbar

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studiekontakt

Studera Kontakt Backup

Studieorter

    • Tyrol
      • Innsbruck, Tyrol, Österrike, A-6020
        • Rekrytering
        • Medical University of Innsbruck
        • Kontakt:
        • Kontakt:
        • Huvudutredare:
          • Christoph Binder, MD
        • Huvudutredare:
          • Martin Wald, MD
        • Huvudutredare:
          • Burkhard Simma, MD

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

1 dag till 5 år (Barn)

Tar emot friska volontärer

Nej

Kön som är behöriga för studier

Allt

Beskrivning

Preterm-born group:

Inclusion Criteria:

  1. Extremely preterm infants with a birth weight of 500-1250g.
  2. Feeding is NPO or exclusive human milk prior to enrollment.
  3. Parent(s) willing to sign informed consent.-

Exclusion Criteria:

  1. Infants with a birth weight <500g or >1250g
  2. Subjects diagnosed with inborn errors of metabolism such as galactosemia, phenylketonuria
  3. Subjects who have not been NPO or fed exclusive human milk diet prior to enrollment.
  4. Presence of major congenital malformation.
  5. Presence of intestinal perforation or Stage 2 Necrotizing enterocolitis prior to enrollment.
  6. Parent(s) not willing to sign informed consent.
  7. Unable to participate for any reason based on the decision of the study investigator (e.g. unlikely to survive the study period).

Term-born group:

Inclusion criteria

  1. Term-born children with an adequate birth weight
  2. Parent(s) willing to sign informed consent

Exclusion criteria

  1. Subjects with acute or chronic illness
  2. Parent(s) not willing to sign informed consent

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Behandling
  • Tilldelning: Randomiserad
  • Interventionsmodell: Parallellt uppdrag
  • Maskning: Enda

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Aktiv komparator: Randomized study product group

receiving study product (human milk fortifier "Humavant") until a gestational age of 36 weeks

Premature infants are randomized to either:

  1. An exclusive human milk diet which contains mother's milk or pasteurized donor human milk and the human milk fortifier until 36 weeks of gestation; OR
  2. Human milk (as long as available) and the human milk fortifier (as long as human milk is available) until a maximum of 32 weeks of gestation and thereafter human milk with a bovine-based fortifier or preterm formula.

After 36 weeks of gestation, human milk with a bovine-based fortifier or preterm formula is used in both groups. As a control group, term-born age-matched controls are included.

Aktiv komparator: Randomized control group

receiving study product until a gestational age of 32 weeks and reference product (bovine based fortifier or bovine formula) after 32 weeks of gestation

Premature infants are randomized to either:

  1. An exclusive human milk diet which contains mother's milk or pasteurized donor human milk and the human milk fortifier until 36 weeks of gestation; OR
  2. Human milk (as long as available) and the human milk fortifier (as long as human milk is available) until a maximum of 32 weeks of gestation and thereafter human milk with a bovine-based fortifier or preterm formula.

After 36 weeks of gestation, human milk with a bovine-based fortifier or preterm formula is used in both groups. As a control group, term-born age-matched controls are included.

Inget ingripande: Term control group

Term-born controls as a reference group for outcome parameters

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Fasting blood glucose
Tidsram: "First day of life" up to "five years of life"

Primary outcome is the difference in fasting blood glucose at five years of age

"First day of life" up to "five years of life"
Blood pressure
Tidsram: "First day of life" up to "five years"

Primary outcome is the difference in blood pressure at five years of age

"First day of life" up to "five years"
Distensibility of aorta
Tidsram: "First day of life" up to "five years"

Primary outcome is the difference in the distensibility of the descending aorta using validated echocardiographic protocols at five years of age

"First day of life" up to "five years"

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Fasting blood glucose
Tidsram: "First day of life" up to "24 months"

Secondary outcome is fasting glucose at a corrected age of one and two years.

"First day of life" up to "24 months"
Blood pressure
Tidsram: "First day of life" up to "24 months"

Secondary outcome is blood pressure at a corrected age of one and two years.

"First day of life" up to "24 months"
BMI
Tidsram: "First day of life" up to "five years"

Secondary outcome is BMI at five years of age, weight in kilograms and height in meters will be combined to report BMI in kg/m2

"First day of life" up to "five years"
Insulin sensitivity
Tidsram: "First day of life" up to "five years"

Secondary outcome is insulin sensitivity at five years of age

"First day of life" up to "five years"
Lipid profile
Tidsram: "First day of life" up to "five years"

Secondary outcome is lipid profile at five years of age

"First day of life" up to "five years"

Andra resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Fasting blood glucose
Tidsram: "five years of age"

Difference in fasting blood glucose between preterm- and term-born children at five years of age

"five years of age"
Blood pressure
Tidsram: "five years of age"

Difference in blood pressure between preterm- and term-born children at five years of age

"five years of age"
Distensibility of the descending aorta
Tidsram: "five years of age"

Difference in the distensibility of the descending aorta between preterm- and term-born children using validated echocardiographic protocols at five years of age Results will be compared to results of term-born children

"five years of age"
BMI
Tidsram: "five years of age"

Difference in BMI between preterm- and term-born children at five years of age, weight in kilograms and height in meters will be combined to report BMI in kg/m2

"five years of age"
Insulin sensitivity
Tidsram: "five years of age"

Difference in insulin sensitivity between preterm- and term-born children at five years of age

"five years of age"
Lipid profile
Tidsram: "five years of age"

Difference in lipid profile between preterm- and term-born children at five years of age

"five years of age"

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Utredare

  • Huvudutredare: Ursula Kiechl-Kohlendorfer, MD, MSc, Medical University Innsbruck

Publikationer och användbara länkar

Den som ansvarar för att lägga in information om studien tillhandahåller frivilligt dessa publikationer. Dessa kan handla om allt som har med studien att göra.

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

9 oktober 2020

Primärt slutförande (Beräknad)

1 juni 2028

Avslutad studie (Beräknad)

1 juni 2028

Studieregistreringsdatum

Först inskickad

26 maj 2020

Först inskickad som uppfyllde QC-kriterierna

30 maj 2020

Första postat (Faktisk)

4 juni 2020

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

18 september 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

15 september 2026

Senast verifierad

1 september 2026

Mer information

Termer relaterade till denna studie

Andra studie-ID-nummer

  • NEOVASC
  • 868624 (Annat bidrag/finansieringsnummer: Austrian Research Promotion Agency)

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

NEJ

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Nej

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera